Home › Funds › ADAR1 Capital Management, LLC › DBVT
ADAR1 Capital Management, LLC position in DBVT
DBV TECHNOLOGIES S A · Health Care
ADAR1 Capital Management, LLC reported holding 2,010,831 shares of DBVT (DBV TECHNOLOGIES S A) in its Q3 2026 13F filing — a position valued at US$23.6M, representing 1.30% of its reported portfolio and ranking #15 among its reported holdings. ADAR1 Capital Management, LLC has disclosed DBVT holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How ADAR1 Capital Management, LLC's DBVT position evolved
ADAR1 Capital Management, LLC first disclosed a stake in DBVT in Q1 2026 at 1,012,866 shares (US$21.2M). The position peaked in Q3 2026 at 2,010,831 shares, worth US$23.6M. Across 3 filings, ADAR1 Capital Management, LLC increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 2,010,831 shares valued at US$23.6M — an increase of 1,482,536 shares quarter over quarter.. Notable position changes include a 48% trim in Q2 2026 (shares fell 28% over the following quarter), a 281% increase in Q3 2026 (shares fell 6% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 1.01M | $21.16M | New |
| Q2 2026 | 528.29K | $8.66M | Reduce |
| Q3 2026 | 2.01M | $23.65M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About DBVT and 13F data
DBVT (DBV TECHNOLOGIES S A) is a Health Care company. 44 other funds we track also report a position in DBVT — the largest reported positions include MPM BioImpact LLC (US$60.1M), Siren, L.L.C. (US$27.7M), PERCEPTIVE ADVISORS LLC (US$27.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding DBVT
- MPM BioImpact LLC 3.67M sh · $60.13M · Q2 2026
- Siren, L.L.C. 2.36M sh · $27.71M · Q3 2026
- PERCEPTIVE ADVISORS LLC 1.65M sh · $27.11M · Q2 2026
- Vivo Capital, LLC 1.84M sh · $21.69M · Q3 2026
- Patient Square Capital LP 1.11M sh · $13.00M · Q3 2026
- Octagon Capital Advisors LP 574.20K sh · $9.42M · Q2 2026
- Redmile Group, LLC 410.44K sh · $6.73M · Q2 2026
- Elmind Capital, LP 265.00K sh · $4.35M · Q2 2026
- Ishara Investments LP 270.00K sh · $3.18M · Q3 2026
- GREAT POINT PARTNERS LLC 156.91K sh · $2.57M · Q2 2026
- Yiheng Capital Management, L.P. 170.14K sh · $2.00M · Q3 2026
More on ADAR1 Capital Management, LLC
FAQ
How long has ADAR1 Capital Management, LLC held DBVT?
ADAR1 Capital Management, LLC has disclosed DBVT holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is ADAR1 Capital Management, LLC's current position in DBVT?
As of Q3 2026, ADAR1 Capital Management, LLC holds 2.01M shares of DBVT (DBV TECHNOLOGIES S A), valued at $23.65M, representing 1.30% of its reported portfolio and ranking #15.
Has ADAR1 Capital Management, LLC been buying or selling DBVT?
In the latest 13F filing (Q3 2026), ADAR1 Capital Management, LLC increased its position in DBVT. The position peaked in Q3 2026 at 2.01M shares.
Which other funds hold DBVT?
Other major institutional holders of DBVT include MPM BioImpact LLC, Siren, L.L.C., PERCEPTIVE ADVISORS LLC, among 44 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.